Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may predict arthritis drug success

NCT ID NCT03561649

Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to find blood markers that can predict whether the drug adalimumab will successfully treat ankylosing spondylitis after 6 months. Researchers analyzed blood samples from 50 adults starting adalimumab for the first time. The goal was to create an algorithm to help doctors identify which patients are most likely to benefit from the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jun 2018

Finished

May 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with spondyloarthritis validating ASAS or modified New York criteria for which adalimumab treatment is indicated, and performing the pre-biotherapy assessment; * Between 18 and 70 years old; * Biotherapy naive; * Who can be regularly monitored for 6 months; * Able to take all the treatment; * Effective contraception for patients of childbearing age (oral contraceptive, intrauterine device, implant, spermicide, surgical sterilization or abstinence) during the study and at least for 5 months after the last injection; * Able to read and understand the terms of the protocol; * Having dated and signed the informed consent form of the trial; * Affiliated to a social security scheme. Exclusion Criteria: * Patients having a contraindication to an anti-TNF; * Surgical operation scheduled during the trial; * Having difficulty understanding the French language; * Having impaired upper functions (dementia of Alzheimer type, etc...); * Psycho-social instability incompatible with regular follow-up (homeless, addictive behavior, history of psychiatric pathology or any other comorbidity which would make a free and informed consent impossible or limit adherence to the protocol); * Having previously received a biotherapy. There is no other exclusion criteria taking into account prior therapies and the duration of these therapies; * Described in articles L.1121-5 to L.1121-8 of the Personal Status Code: pregnant, parturient and nursing women; persons in detention by judicial or administrative decision; adults subject to a legal protection order; * Already participating in interventional research.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spondylitis, ankylosing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Spondylarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spondylitis, ankylosing

Contacts and locations

Locations

  • CH de Belfort

    Belfort, 90016, France

  • CHRU de Clermont-Ferrand

    Clermont-Ferrand, 63003, France

  • CHU de Besançon

    Besançon, 25030, France

  • CHU de Grenoble

    Échirolles, 38434, France

  • CHU de Saint-Etienne

    Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.